MTATP6P9

Across TCGA pan-cancer cohorts, MTATP6P9 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MTATP6P9 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MTATP6P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTATP6P9 expression acts as an unfavorable survival marker.

LUAD, ACC, and ESCA are the cancer types where MTATP6P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.400	0.816	<.001	120	view →
ACC	OS	Tertile	III,IV	0.145	0.766	<.001	63	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
LUSC	DFS	Tertile	II,III,IV	0.149	0.760	<.001	36	view →
KIRC	DFS	Tertile	IV	0.106	0.640	<.001	36	view →
SARC	OS	Tertile	All	0.148	0.518	.011	24	view →
READ	DFS	Tertile	All	0.111	0.799	.001	18	view →
LIHC	DFS	Tertile	All	0.206	0.445	.008	15	view →
GBM	DFS	Tertile	All	0.095	0.291	.029	9	view →
STAD	OS	Tertile	III,IV	0.187	0.528	.044	9	view →
PCPG	OS	Tertile	All	0.571	0.963	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MTATP6P9–LUAD (OS)

Open the LUAD breakdown →